The Hemodynamic Response to Prolonged Dobutamine Infusion

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2011 by Hadassah Medical Organization
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01042873
First received: January 5, 2010
Last updated: July 3, 2011
Last verified: June 2011

January 5, 2010
July 3, 2011
January 2010
December 2015   (final data collection date for primary outcome measure)
Heart rate [ Time Frame: 3 hours ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01042873 on ClinicalTrials.gov Archive Site
Systolic blood pressure [ Time Frame: 3 hours ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
The Hemodynamic Response to Prolonged Dobutamine Infusion
Not Provided

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.

Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

Not Provided
Interventional
Phase 4
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
  • Healthy
  • Heart Failure
Drug: 3 hours intravenous dobutamine
Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
Intravenous dobutamine
3 hours infusion of dobutamine
Intervention: Drug: 3 hours intravenous dobutamine
Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2019
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy subjects

Exclusion Criteria:

  • consumption of any medications during the 2 weeks prior to the study
  • history of chest pain or tachycardia
Both
18 Years to 40 Years
Yes
Israel
 
NCT01042873
0355-09-HMO-CTIL, 0355-09-HMO
Yes
Mordechai Muszkat, MD, Hadassah-Hebrew University Medical Center
Hadassah Medical Organization
Not Provided
Not Provided
Hadassah Medical Organization
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP